Though Moderna stock soared back then, in more recent times, the stock has stumbled. The company has seen vaccine sales ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 4% in the afternoon session after the broader biotech sector experienced a strong rebound, lifting shares of companies within the industry.

Moderna earns the No. 356 rank among its peers in the Medical-Biomed/Biotech industry group. Exact Sciences EXAS, Genmab ADR GMAB and Krystal Biotech KRYS are among the top 5 highly rated stocks ...

Since that moment, Moderna has taken steps to pave the path to long-term growth -- from cutting costs to focusing on its vast ...

Moderna, Inc. has rallied ~23%, but rated a Sell due to deteriorating fundamentals. Learn more about MRNA stock here.

Moderna Inc (NASDAQ:MRNA) shares are trading lower on Friday afternoon, giving back a portion of the gains seen on Thursday. Here’s what investors need to know. What To Know: The stock spiked on ...

Mixed earnings results were being mentioned on Thursday as possible catalysts behind Thursday's stock-market action. Shares of Moderna Inc. were up more than 3% after the vaccine maker reported a ...

Get the latest Moderna (MRNA) stock analysis: balanced risk-reward, new vaccine launches, and pipeline insights. See why we ...

The exec donated $176 million after-tax to charity last year and pledged to continue, but analysts still aren't sure he should be making so much.

After donating $176 million in proceeds from his original stock options in 2023, Stéphane Bancel is taking a different path ...

Moderna, Inc. is a biotechnology company specializing in the discovery and development of mRNA-based medicines. The company leverages its mRNA technology platform to address a broad range of diseases, ...